Rani Therapeutics has appointed Nicholas Maestas as its new Chief Financial Officer, effective immediately. He succeeds Svai Sanford, who announced his departure in May 2026 to pursue other professional opportunities. Maestas brings more than 10 years of experience across several clinical-stage biotechnology companies, most recently serving as CFO and head of corporate strategy at Tempest Therapeutics. Prior to that, he led financial analysis and strategic planning at Alector, overseeing a collaboration with GSK. Rani Therapeutics shares closed Monday at $0.76, up 3.91%, and were trading down 0.61% in after-hours trading.
Rani Therapeutics Holdings IncAppointment of new CFO is a management change; no clear positive or negative signal.
Alector Inc
GSK plc
Tempest Therapeutics Inc